New amfAR Grants Advance HIV Cure and Post-Treatment Control Studies

Awards totaling $1.16 million will support ‘Trojan horse’ approach to curing HIV
and effort to unlock the secrets of post-treatment control

NEW YORK CITY, August 27, 2019 — Through the amfAR Research Consortium on HIV Eradication (ARCHE), a grant program that fosters collaboration among teams of scientists, amfAR has awarded new grants totaling $1.16 million to advance a pair of innovative research studies attacking HIV from very different angles.   

Keith Jerome, Ph.D., of the University of Washington, Seattle, was awarded $344,000 for a project that aims to advance a gene therapy strategy for curing HIV. Gene therapy is emerging as one of the most promising interventions across all of biomedical science, including HIV, but it carries a number of risks and challenges. Scientists need to find ways to improve the efficiency of appropriately altering DNA, effectively target the correct cells, and enable the therapy to safely persist long enough to have an effect.

Moreover, a substantial limitation of current approaches is their cost in the clinic, which can be as much as $2 million or more. amfAR’s ARCHE-GT consortium plans to reduce costs by developing in vivo gene therapy in which the gene-engineering tools are injected directly into the patient. These tools are delivered inside vectors, which function as ‘Trojan horses.’

Dr. Jerome’s team plans to compare which of 11 vectors delivers the gene-editing tools most effectively to the various specific tissues that are being targeted. These lead candidates will then be used in future studies of combination in vivo gene therapy interventions.

Another area of HIV research in which amfAR is particularly interested is post-treatment control. Post-treatment controllers (PTCs) are HIV-positive individuals who, unlike the majority of people living with HIV, are able to control their virus after stopping antiretroviral therapy (ART). But discovering the mechanisms of this control has proven difficult since the rarity of PTCs has so far precluded analysis of a sufficient number of samples.

amfAR’s ARCHE-PTC collaboration consists of the world’s leading experts in PTC research and brings together clinical cohorts of PTCs from all over the world, including an all-female cohort from Cameroon, under one streamlined analysis plan. Dr. Jonathan Li of Brigham and Women's Hospital in Boston has assembled an impressive cohort of post-treatment controllers from one of the largest HIV clinical trial networks in the world.

Supported by an amfAR grant of $815,000, Dr Li and his team will gather and analyze samples from this multinational PTC cohort and will be able to employ cutting-edge tools to investigate whether characteristics of the virus or immunologic responses can predict post-treatment control. Discovering what leads to post-treatment control in some people could help to achieve durable ART-free control in all people living with HIV.

“We’re excited to be supporting these immensely talented research teams and their very different but very promising avenues of investigation,” said Dr. Rowena Johnston, amfAR vice president and director of research. “These research areas have enormous potential for giving us the tools to control the virus without the need for lifelong treatment or, in the case of gene therapy, to eliminate it altogether. Either outcome could dramatically alter the lives of the millions of people living with HIV worldwide.”

Former Krim Fellow Wins Prestigious NIH Award

Dr. Alon Herschhorn

Dr. Alon Herschhorn

Dr. Alon Herschhorn is an Assistant Professor of Medicine in the Division of Infectious Diseases and International Medicine at the University of Minnesota. He has previously held a faculty position and conducted research at the Dana-Farber Cancer Institute and Harvard Medical School, and is the recipient of a Rothschild Fellowship and an amfAR Mathilde Krim Fellowship in Basic Biomedical Research. Dr. Herschhorn has now won a 2019 Avenir Award for HIV/AIDS Research for a project investigating the pathways used by HIV to escape broadly neutralizing antibodies. He is also building a platform to bioengineer a vaccine able to more precisely target the HIV envelope proteins (Env) for elicitation of broadly neutralizing antibodies. Dr. Herschhorn hopes that his in vitro and in vivo studies will lead the way to new therapeutic and preventive strategies against HIV.

amfAR: How did you become interested in HIV research?

Dr. Herschhorn: When I started my undergraduate studies, I was looking for a challenging research direction that would be both important and have an impact on human health. At that time, there were only a few FDA-approved drugs for antiretroviral therapy, and HIV quasispecies—“swarms” of mutated viruses—in patients were rapidly developing resistance to these drugs. The HIV pandemic was spreading at an alarming rate and there were emerging efforts to prevent transmission.

These were difficult times and I thought that understanding the complex biological processes involved in the HIV life cycle would provide insights and tools for developing new strategies for interventions. I started working on two HIV enzymes: reverse transcriptase and integrase, which are main targets of antiretroviral drugs. Then, during my postdoctoral studies, I focused on the molecular mechanisms of Env function, which is key to the development of an effective HIV vaccine.  

I would like to add that I was lucky to be able to do what I love through my career and encourage researchers starting their scientific journeys to trust their hearts to do what they really love. Everything else will follow.

amfAR: It is often difficult for early career scientists to find funding. How did our Mathilde Krim Fellowship help to advance your research career?

Dr. Herschhorn: I will always be grateful to the Mathilde Krim Fellowship for advancing my research career. The prestigious fellowship was not only an acknowledgment of my past scientific achievements and vision for the future, but it was the first time that I learned how to responsibly manage a budget for a scientific project, how to interact with a program administrator, and how to apply for NIH funding after participating in a workshop on the NIH grant mechanisms.

The second phase of the Krim Fellowship was critical. At that time, funding in our laboratory was rapidly decreasing and my visa status depended on a sponsor. Without the support of amfAR funds, I probably would have had to leave the U.S. and start over. Luckily, the second phase of funding provided me extra time and support to continue my studies and I laid new groundwork for understanding HIV Env function and inhibition. These concepts opened new opportunities for research and were the basis of my successful application for the Avenir Award (NIH Director's New Innovator Award mechanism) from the National Institute on Drug Abuse. I would like to personally thank Jonathan Miller and Dr. Marcella Flores for their help during the grant period. 

amfAR: Can you summarize your work since completing the Mathilde Krim Fellowship?

Dr. Herschhorn: The Krim Fellowship provided me with the time and support to establish a new platform for dissecting HIV Env function. After completing the fellowship, I used these tools to study the molecular mechanisms of HIV entry into the cell. In collaboration with the groups of Dr. Walther Mothes of the Yale School of Medicine and Dr. Peter Kwong of the NIH, we identified a switch that regulates changes in the structure of HIV Env during cell entry. We showed that the regulatory switch controls opening of HIV Env from a closed to a more open conformation during the interactions with the CD4 cellular receptor.

I have also developed a new system to monitor HIV latency and replication at single cell and population levels. The system, which is based on concepts published by the group of Dr. Eric Verdin of the University of California, San Francisco, was distributed to more than ten laboratories around the world and is now being used as part of scientific collaborations to understand the alternative outcomes (viral latency or active replication) of HIV infection in target cells.

Since my appointment as Assistant Professor at the University of Minnesota, I have been applying the knowledge and tools that I developed during and after the Krim Fellowship to bioengineer new Env-based immunogens for HIV vaccine development, to delineate the pathways used by HIV to escape broadly neutralizing antibodies—specialized antibodies able to inactivate diverse types of HIV—and to elucidate the network of HIV-host interactions during HIV infection.

amfAR: What are your hopes for the HIV research field in the next five years?

Dr. Herschhorn: There are several exciting research directions that may lead to insights into the interactions of HIV with the immune system and HIV pathogenesis.

Multiple clinical trials are now testing the effect of administration of broadly neutralizing antibodies to people who live with HIV. Evidence from a minority of patients suggests that, in a few cases, HIV may be suppressed for a long period of time. I hope that in the next five years we will understand why these antibodies have long-lasting effects in some patients, how long HIV can be suppressed, and the limitations of the ability of HIV to develop resistance in vivo.  

Several vaccine trials have begun. One design will test the ability of a germline-targeting immunogen to elicit broadly neutralizing antibodies specific to the CD4 binding site of HIV Env. I hope that the results of this trial will guide new strategies to elicit broadly neutralizing antibodies in humans.

We need a method for robust measurement of the latent, replication competent reservoir (of HIV with all the components needed to assemble virions) in infected individuals. I hope that advances in next generation technologies will lead to a simple assay capable of measuring the size of the replication competent HIV reservoir in patients.

As a final comment, I would like to say that I am grateful to many people that helped me along the way: Drs. Ashley Haase, Timothy Schacker, and Reuben Harris, who provided endless support since my arrival to the University of Minnesota; Dr. Joseph Sodroski, my postdoctoral mentor at Harvard Medical School and Dana-Farber Cancer Institute; Dr. Alan Engelman, who offered me a short-term position when I most needed one, Dr. Walther Mothes for the continuous support, and Dr. Amnon Hizi, my adviser during my graduate studies.

Designing a Better Model for HIV Infection


Dr. Amit Sharma

Dr. Amit Sharma

Monkey models are critical to exploring almost everything related to human HIV-1 infection, from vaccines to treatment and cure. But HIV-1 does not persistently infect the small monkeys known as macaques available for studies. Instead, these primates are susceptible to SIV—an HIV-like virus that can cause AIDS in monkeys.

Researchers study macaques infected with SHIVs—a combination of SIV and HIV—which resemble the activity of HIV in a monkey. But SHIVs have a limitation: They don’t grow well in monkey cells, partly because the viral envelope triggers production of interferons—proteins produced by the body shortly after infection that serve as a main defense against many viruses.

The Research Question

In this study, the challenge was to identify the factors involved in interferon-based limits to growth of SHIVs.


Researchers used a technique known as RNA-Seq to capture all the genes activated by interferon in macaque immune cells. By examining the proteins produced by those genes they could home in on those most likely to interfere with the HIV envelope—the viral culprit known to result in interferon production.

They identified several interferon-induced transmembrane (IFITM) proteins, which are present in macaques but not in humans. Scientists used CRISPR-Cas9 technology (a gene-editing tool) to delete IFITMs in monkey cells and saw that SHIV could grow, even in the presence of interferon. These findings confirmed that it was the IFITMs—activated by interferon—that prevented SHIVs from growing well in monkey cells.


The authors note that the study “may shed light on new approaches to improve the SHIV/macaque models by rationally designing SHIVs while maintaining as much as possible of the HIV-1 character of the virus.” It may also help to define how other viruses adapt to host restriction factors, enabling transmission across species.

amfAR’s Role

Dr. Amit Sharma is an Assistant Professor at Ohio State University and is funded by amfAR.

Original Article

Dr. Laurence is amfAR’s senior scientific consultant.


amfAR Second Largest Funder of HIV Cure Research

Modest global HIV cure funding increases sustained in 2018

In a new report, amfAR has been named the second largest HIV cure research funder in the world—second only to the U.S. National Institutes of Health. Released at the 10th IAS Conference on HIV Science in Mexico City, Global Investment in HIV Cure Research and Development in 2018 shows total global investments continuing to steadily increase.

The report—compiled by the Cure Resource Tracking Group, a collaboration between AVAC and the International AIDS Society—estimates global investments in HIV cure research of $323.9 million in 2018, a 12 percent increase over the $288.8 million invested in 2017. Compared to the $88.1 million invested since tracking began in 2012, this is a 268 percent increase.

The public sector accounted for the majority of funding, with the remaining $19.7 million invested by philanthropies. amfAR accounted for more than half of all philanthropic investment, with $10.9 million in funding last year.

“amfAR is proud to be recognized for its commitment to HIV cure research,” said Dr. Rowena Johnston, amfAR Vice President and Director of Research. “We remain steadfast in our pursuit of the most innovative and promising paths toward a cure.”

“The inclusion of ‘cure’ in the global response should not direct funding away from treatment, prevention and care programmes, or from biomedical research on HIV and its consequences, including vaccine and other prevention research,” noted the report’s authors. “However, it is imperative that donors, governments and the AIDS community make a viable and sustained economic investment in HIV cure research.”

Read the full report here.

How HIV Hijacks Cell Machinery


Dr. Jonathan Richard

Dr. Jonathan Richard

For nearly half a billion years, retroviruses and the animal immune systems they infect have each evolved strategies to outmaneuver the other in a kind of molecular arms race. HIV—which crossed into humans in the early 1900s—has inherited and advanced the strategies of its retrovirus predecessors.

HIV uses the molecular machinery inside the host cell to replicate. Studying interactions between the viral and host proteins reveals mechanisms of infection including viral replication, the host response, and how the virus eludes that response.

The Research Question

In two new studies, amfAR-funded researchers reported on methods used by HIV to impede immune defenses. In one study, Dr. Jonathan Richard of Université de Montréal, Centre de Recherche du CHUM and colleagues investigated how a viral protein targeted multiple cellular defenses at once. In another study, Dr. Judd Hultquist of Northwestern University School of Medicine and colleagues investigated how the virus “hijacked” host proteins involved in an antiviral defense pathway.

Dr. Judd Hultquist

Dr. Judd Hultquist


HIV virions bud from the cell membrane and then travel to infect a new cell. The host protein BST-2, or tetherin, defends against budding by tethering virions to the cell membrane. In response, HIV uses its viral protein Vpu to prevent BST-2 from tying down the emerging virion.

Vpu also thwarts another host defense: the recognition and killing of infected cells by natural killer (NK) cells. Dr. Richard and colleagues reported that the drug interferon alpha (IFNa) increased the amount of BST-2 in the cell, requiring more Vpu to counteract it. This left less Vpu available to stop NK cells, allowing them to hunt and kill virally infected cells.

Dr. Hultquist and colleagues used an innovative combination approach to investigate how the viral protein Vif hijacks the machinery a cell uses to degrade unwanted proteins, causing it instead to destroy APOBEC3—an important antiviral host cell protein. The researchers noted that better understanding these virus and host interactions could offer new targets for antiviral therapies and vaccines.


These studies each show that viral and host immune system interactions can be manipulated to develop more effective treatments.

amfAR’s Role

Both Drs. Jonathan Richard and Judd Hultquist are funded by amfAR.

Original Articles

Dr. Flores is amfAR’s associate director of research.

Mapping an HIV Vaccine Target

Researchers gain new insights into the potential power of broadly neutralizing antibodies 


Dr. Marit Van Gils

Dr. Marit Van Gils

There is currently no HIV vaccine capable of eliciting protective immunity. One promising area of vaccine research has focused on broadly neutralizing antibodies (bNAbs)—specialized antibodies capable of inactivating diverse types of HIV. Of interest to researchers are a small number of people living with HIV called “elite neutralizers” who naturally develop bNAbs, providing models for vaccine development. 

bNAbs obtained from such elite neutralizers are being studied for their possible use in HIV prevention, treatment, and cure interventions. While they have shown much potential—inactivating about half of all variants of HIV—there remain obstacles such as how to extend the duration of protection and how these antibodies can more effectively inactivate the virus.  

The Research Question 

Last year, researchers were able to protect monkeys against SIV—an HIV-like virus that causes disease similar to AIDS—through the infusion of bNAbs sourced from elite neutralizers. The study found that genetically modified bNAbs could provide long-term protection against the virus, and the modification did not affect the way they bound to the virus.  

Previous studies have demonstrated which region of the virus is vulnerable to bNAbs. In this study, amfAR-funded researchers asked: How do changes in the way binding at this region occurs aid recognition and neutralization of HIV? 


Dr. Gabriel Ozorowski

Dr. Gabriel Ozorowski

Researchers studied the region of HIV recognized by a bNAb obtained from an elite neutralizer. They used highly sophisticated scanning procedures such as ultra-high resolution cryo-electron microscopy—which examines the topography of proteins—to capture the molecular interactions between the antibody and the participant’s own HIV. Scientists used these stop motion animation-like scanning procedures to locate points of contact between the antibody and the virus, and to piece together specific interactions that lead to the antibody’s potent ability to neutralize HIV. 

Researchers focused on interactions at the fusion peptide—a viral protein that folds back on itself to pull the bulk of the virus inside the cell. The fusion peptide is surrounded by a shield of sugar molecules that makes it largely inaccessible. Yet some antibodies have been known to penetrate the shield and neutralize the fusion peptide. The scanning techniques used by the researchers here revealed that this elite neutralizer’s bNAb could interact with the fusion peptide in an entirely new way. They also found that the fusion peptide is much more flexible than previously thought, making it amenable to targeting by this and perhaps other antibodies.   


Knowledge of how the HIV fusion peptide can twist into multiple conformations, or shapes, illuminates antibody recognition strategies that can be used for HIV vaccine design.


amfAR’s Role 

Both Drs. Ozorowski and van Gils are funded by amfAR through the Mathilde Krim Fellowship program.


Original Article


Dr. Laurence is amfAR’s senior scientific consultant.

Combination Treatment Cures Mice of HIV

Antiretroviral therapy (ART) has been extremely effective at reducing HIV in the blood to below levels of detection, but less able to stop viral activity in the tissues. Efforts to achieve a cure for HIV would therefore be aided by stopping this source of virus that continually feeds the HIV reservoir.

Dr. Howard Gendelman of the University of Nebraska Medical Center has developed LASER ART, a slow-release, long-acting nanomedicine version of ART that penetrates deep into tissues to effectively extinguish this source of viral activity. This powerful new technology raises the question: With a newly contained viral reservoir, could the right intervention have a chance to cure HIV?

In a July article in Nature Communications, Dr. Gendelman and Dr. Kamel Khalili, of the School of Medicine at Temple University, demonstrate that it may be possible.

Using humanized mice infected with HIV and treated with LASER ART, Dr. Khalili administered CRISPR, a protein that acts like a molecular scissor, to cut out HIV DNA from infected cells. Sequential treatment with LASER ART followed by CRISPR eliminated viral rebound in two of six mice when ART was stopped—a key measure to determine whether a cure has been achieved.

The research team went a step further, however, transferring cells from these two potentially cured mice into different, uninfected mice and confirming that no HIV infection was transmitted.

These encouraging results are a boon to the field of gene therapy, which is increasingly turning to various types of molecular scissors, including CRISPR, Brec1, and others to eliminate HIV from the body. amfAR’s is currently funding several such innovative gene therapy approaches through its ARCHE-GT collaborative grant initiative.

Dr. Flores is amfAR’s associate director of research.

amfAR Advances Collaborative Bioengineering Studies Aimed at Curing HIV

New amfAR grants support third phase of high-tech projects
using nanotechnology and protein “fingerprinting”

Media Contact:

Mary Pavlu, amfAR
P: 212.806.1602

NEW YORK, April 12, 2019 – amfAR, The Foundation for AIDS Research, has awarded new funding to researchers using cutting-edge technology to address the main barrier to a cure for HIV: the persistent reservoirs of virus not cleared by antiretroviral therapy. Totaling $1.6 million, this new round of Investment grants launches the critical third phase of two research projects launched in 2017.

Investment awards are milestone-based grants for research studies undertaken over four years in three phases. In this third phase, bioengineers are working in partnership with leading HIV cure scientists to tackle some of the most difficult challenges in HIV cure research. The grants are part of amfAR’s $100 million Countdown to a Cure for AIDS initiative, which is aimed at developing the scientific basis of a cure by the end of 2020.

“At amfAR, we believe that combining innovation with collaboration is the surest way to a cure for HIV,” said amfAR CEO Kevin Robert Frost. “These awards are an outstanding example of that philosophy in action and we will follow the progress of these exceptional grantees with great interest.” 

One of the biggest challenges in HIV cure research is that until now, it has been impossible to pinpoint and kill HIV reservoir cells, since no one has been able to identify a unique characteristic, or marker, that sets them apart from non-reservoir cells. Dr. Hui Zhang of Johns Hopkins University, a leading expert in the field of mass spectrometry, is applying this protein “fingerprinting” technique to the challenge.

In the first two phases of the study, Dr. Zhang used mass spectrometry to scan the surface of human cells for proteins that discriminate between latently infected and uninfected cells. After scanning a variety of cell lines, she identified 17 potential targets. In phase three, Dr. Zhang is teaming up with HIV scientist Dr. Weiming Yang, also of Johns Hopkins University, to determine in a preclinical study whether specifically killing cells displaying any of these 17 proteins will eliminate the latent reservoir.

On the West Coast, Dr. Keith Jerome and bioengineer Dr. Kim Woodrow, both at the University of Washington in Seattle, are focusing on identifying a potent latency reversing agent (LRA) that can shock the reservoir out of latency, the first stage in a “shock and kill” strategy to cure HIV.  

One of the most effective classes of LRAs developed to date, ingenols, has significant toxic side effects and can lead to expansion of the viral reservoir. To reduce this toxicity and prevent expansion of the reservoir, Drs. Woodrow and Jerome are using nanoparticles—highly versatile vehicles that, like a Trojan horse, can deliver multiple drugs to a single cell. To date, the researchers have formulated nanoparticles loaded with LRAs including an ingenol and have succeeded in greatly reducing toxicity in a mouse model. In the next phase, they will test their nanoparticles for elimination of the reservoir in a preclinical study.

“These four-year investment grants have enabled us to support some remarkable collaborative research that needs more than just a year or two to show meaningful results,” said Dr. Rowena Johnston, amfAR vice president and director of research. “If these researchers manage to accomplish what they’ve set out to do, we will have overcome two of the biggest obstacles standing in the way of a cure for HIV.” 



About amfAR: 

amfAR, The Foundation for AIDS Research, is one of the world's leading nonprofit organizations dedicated to the support of AIDS research, HIV prevention, treatment education, and advocacy.  Since 1985, amfAR has invested nearly $550 million in its programs and has awarded more than 3,300 grants to research teams worldwide.

Could Gene Therapy Cure HIV?

Upcoming Advances in HIV Gene Therapy

In August, scientists will discuss their latest findings at the 5th Conference on Cell & Gene Therapy for HIV Cure in Seattle. amfAR’s research will feature prominently, including an update from ICISTEM, the amfAR-initiated and funded European consortium that reported a few months ago on the London patient. Several members of amfAR’s ARCHE-GT consortium will also report on their combination approach to cutting HIV DNA out of infected cells and boosting T cell and antibody responses against any remaining virus.


Rowena Johnston, Ph.D.

Rowena Johnston, Ph.D.

The promise of gene therapy is beginning to make its way into the clinic. In 2017, the FDA approved two CAR T cell therapies for cancers of the immune system, and another gene therapy to correct a gene mutation that causes retinal dystrophy. And in May 2019, Zolgensma was approved as a one-time treatment for children under two years of age with spinal muscular atrophy.

The number of FDA-approved gene therapies appears set to grow in the coming years, with nearly 4,000 clinical trials underway to address illnesses ranging from rare inherited conditions to those that rank among the most common killers, including cancer, heart disease, Alzheimer’s disease, and diabetes.

The Research Opportunities

In some respects, HIV is a conceptually simple target because it exists as a strand of DNA—much like a gene—inserted into the normal DNA of human immune cells. Indeed, many research groups are exploring a range of tools that could cut this strand of HIV DNA out of infected cells and thus remove the virus from the body.

However, HIV is a complex virus that provides numerous other avenues of attack. For example, some research groups are exploring whether cutting out the gene for CCR5, and thus removing the CCR5 protein—the main doorway through which HIV enters cells—might cure HIV along similar lines to the Berlin patient’s cure. The HIV remission observed in the London and Düsseldorf patients—members of amfAR’s ICISTEM cohort—lends additional optimism to this approach.

The possibilities don’t end there. Protective genes could be inserted; new or improved immune function could be engineered; individual or multiple HIV genes could be turned off; and any or all of these approaches could be combined with other gene or traditional therapies.

Anticipated Conference Highlights

The conference will begin with a session on stem cell transplantation and gene editing, featuring a plenary talk delivered by ICISTEM researchers. Subsequent sessions will feature updates on CAR T cells and other T cell therapies, as well as lessons from cell and gene therapy in other diseases.

Day two of the conference will focus on in vivo delivery of gene therapy. Researchers from amfAR’s ARCHE-GT consortium will present their progress on using different methods to deliver gene-editing tools, for example via intravenous injection.


Although gene therapy approaches have shown much promise in various diseases including HIV, they are currently very expensive. Thus far, approved gene therapies cost up to $2 million, partly due to the complexity of preparing the gene therapy product. In vivo delivery could make gene therapy substantially less expensive and more easily deliverable to people around the world living with HIV.

amfAR’s Role

amfAR is currently supporting multiple gene therapy approaches to curing HIV and is providing support to the 2019 Conference on Cell & Gene Therapy for HIV Cure.

Conference Information

Researchers looking for more information about the conference, including registration and late-breaker abstract submission, should visit

Dr. Johnston is an amfAR vice president and director of research.

Non-AIDS Defining Illnesses Impact Health in the Age of ART

Antiretroviral therapy (ART) has dramatically reduced mortality rates from both AIDS-related and non-AIDS related diseases of people living with HIV (PLWHIV). But there are important exceptions to this trend: Certain cancers and forms of heart and liver disease remain prominent among PLWHIV.

A Biomarker for the “Active” HIV Reservoir?


HIV persists in a small number of infected cells—the viral reservoir—that are not cleared from the body by antiretroviral therapy. A major goal of HIV cure research is to identify a molecule, or biomarker, that distinguishes these reservoir cells from healthy cells. Having such a biomarker would allow researchers to target these reservoir cells and clear them with precision.  

Co-leader of the study, Dr. Peter Hunt

Co-leader of the study, Dr. Peter Hunt

The Research Question 

In 2017, a team of researchers in France reported that they had found a potential biomarker of the reservoir in the blood—a protein called CD32. In their attempts to replicate the discovery, several other research teams found that CD32 may be a marker of HIV activity in blood cells rather than a specific marker of the latent reservoir. Scientists in this study ask: Could CD32 be a biomarker of HIV activity in the tissues, too? 


Scientists examined gut biopsies from four study participants whose medication had reduced the HIV in their blood to undetectable levels. First, researchers noted that despite having undetectable virus in the blood, about four in every 100,000 cells in the tissue had jump-started activity of the provirus, meaning they had begun the first steps towards producing new viruses. These “actively” infected cells may be the first to re-seed viral infection in the blood if antiretroviral therapy is stopped. 

Next, the researchers explored whether CD32—the possible biomarker—was present in the actively infected cells, and to what degree. Using two separate techniques, the researchers found that those with undetectable virus in the blood had 100 times fewer actively infected cells in the tissue than those with detectable virus in the blood (viremia). But by one assay, between 60 and 100 percent of actively infected cells had CD32, compared to only 20 percent in those with viremia.  

Co-leader of this study, Dr. Timothy Henrich

Co-leader of this study, Dr. Timothy Henrich


This study confirms the conclusion of other researchers that CD32 may not be a biomarker of the latent reservoir. However, CD32 may be a biomarker of what might be called the active reservoir—the persistent virus that is probably first to re-seed infection when antiretroviral therapy is stopped. Thinking on the nature of the reservoir is evolving to include not only latent, but also active reservoir, and both are major barriers to a cure. Finding a way to differentiate cells harboring active reservoir from healthy, uninfected cells would be an important advance. 

amfAR’s Role 

The co-lead scientists of this study, Drs. Timothy Henrich and Peter Hunt, are funded by amfAR and are members of the amfAR Institute for HIV Cure Research. 

Original Article


Dr. Flores is amfAR’s associate director of research.

The Ability to Control HIV Without ART Runs in Families

Dr. Steven Deeks

Dr. Steven Deeks

In prior updates, we’ve focused on CCR5, the primary receptor enabling HIV to infect cells. CCR5 is known for its role in the cure of the “Berlin patient” following a bone marrow transplant with donor cells bearing a mutated, thus non-functional, CCR5 protein.

Reporting in the online journal eLIFE, Dr. Steven Deeks of the University of California, San Francisco, and colleagues, found another way that CCR5 is connected to the ability to control HIV without antiretroviral therapy (ART). Interestingly, they also found evidence that this ability is heritable.

Deeks and colleagues sought to define genetic factors enabling a small population of HIV-infected individuals called elite and viremic controllers to maintain viral loads less than 50 or 2000 copies, respectively, without ART. These are considered “functional cures” since the virus is not eradicated—the usual definition of “cure”—but the person does not develop immune problems over time.

The researchers studied 131 such individuals, about half elite and half viremic controllers, some of whom have been infected since 1980. Some had HLA types—cell protein markers—associated with elite control, but those protective genes account for only about 20% of the viral effect.

They discovered that control was related to a natural and partial resistance to infection in controllers and noncontrollers. Further analysis showed that controllers had less CCR5 present on their cells than noncontrollers, and their cells were less permissive to HIV infection. Furthermore, natural resistance to HIV was shown to be inherited, as multiple generations of family members, male and female, from one of the viremic controllers had a similar profile of lowered CCR5.

There have now been at least two instances related to CCR5 in which researchers identified partial or full resistance to HIV. The first is a rare mutation, CCR5-delta32—a defunct CCR5 protein—leading to the cures of the Berlin and London patients after stem cell transplants with cells containing this mutation. The second, in this new study by Deeks and colleagues, is the natural decrease in some elite and viremic controllers who make a normal CCR5 protein, but at much lower levels than people who cannot control HIV.

Studying how and under what circumstances these controllers make lower levels of CCR5 may lead to new discoveries that could inform interventions for a functional cure.

HIV Treatment Interruption: Lessons and Limitations

The recent case of the London patient—potentially the second known case of an HIV cure—highlights a challenge faced by the cure research field: How do you know when an intervention has resulted in a cure?  

To date, the field has used analytic treatment interruption (ATI)—stopping antiretroviral therapy (ART) under the guidance of a doctor—to monitor when, how high, and for how long the virus rebounds. If the virus rebounds, then the question of viral eradication has been answered and the participant can restart ART. But using ATI to determine whether post-treatment control (PTC)—the ability to keep the virus under control in the absence of ART—has been achieved, is a longer and more complex proposition. ATI presents challenges to participants, their partners, and to the researchers seeking to make sense of the data.

Dr. Sharon Lewin

Dr. Sharon Lewin

In the April issue of AIDS, amfAR-funded scientist Dr. Sharon Lewin of Monash University in Melbourne, Australia, documented nearly two decades of studies using ATI to chart achievements and lessons learned. Analyzing 159 ATI clinical trials conducted between 2000 and 2017, Dr. Lewin and colleagues noted a trend to restart ART as soon as virus was detected in plasma, especially after 2014, when the World Health Organization began recommending universal ART.

Prior to 2014, when CD4 count rather than plasma viral load was used as the main criterion to restart ART, researchers were more likely to delay restarting ART to determine whether an intervention had a post-treatment control effect. The trend toward restarting ART sooner alleviates the concern that a patient will unwittingly transmit HIV to a sexual partner and is generally agreed to be safest for the participant, but it comes at a cost to the researchers’ ability to discover effective interventions.

The challenge of when to restart ART was among the topics discussed by more than 40 scientists and clinicians who convened at the Ragon Institute of MGH, MIT and Harvard in July 2018, including amfAR grantee Dr. Dan Barouch and amfAR vice president and director of research, Dr. Rowena Johnston.

The attendees published their recommendations for researchers and clinicians planning ATI studies in The Lancet HIV, aiming to ensure that study designs maximize the knowledge gained and reduce the risk to trial participants. The group agreed that restarting ART should occur any time a participant requests it or if HIV-related conditions emerge.

However, mitigating the risk of transmitting the virus to a partner during a longer ATI to test for PTC was a more difficult challenge. Participants would require comprehensive counseling, including on the use of condoms or pre-exposure prophylaxis (PrEP), and researchers may need to exclude participants who engage in high-risk behavior. Some studies have begun to routinely test for sexually transmitted infections as one indicator of a participant’s use of condoms during ATI.

Until better predictors of curative success are found, or tests proving the absence of an HIV reservoir are developed, ATI will continue to be the gold standard in HIV cure research. By developing better standards and recommendations that guide current and future ATI studies, the field is ensuring that the progress made is safer for the participant and more valuable to the research community.

Dr. Flores is amfAR's associate director of research.

What Stem Cell Transplants Can Teach Us About Curing HIV

amfAR researchers unable to find HIV in London transplant patient

Stem cell transplants are used to treat cancers of the immune system, and are typically used in people for whom other cancer treatments have failed. The stem cells are taken from adult donors or from cord blood, and when transplanted into the recipient, those stem cells mature into a new and healthy immune system.

Sometimes people living with HIV (PLWHIV) develop one of these immune cancers, and they become candidates for stem cell transplants. Under these circumstances, we have an opportunity to learn a lot about how HIV persists even when it’s well controlled by antiretroviral therapy (ART), and how replacing the immune system affects the ability of HIV to persist.

amfAR set up and provided funding to the IciStem consortium so that we could learn some important lessons about curing HIV that could be applied to designing a cure that would work in anyone, whether or not they receive a stem cell transplant. The researchers in IciStem analyze the blood and tissues of HIV-positive transplant recipients. They can then compare the outcomes between people who received transplants that have fully functional CCR5—the main doorway that allows HIV to enter cells— and those whose transplanted cells contained the CCR5-delta32 genetic mutation. This is of particular interest because cells with the genetic mutation are highly resistant to HIV.

Co-Principal Investigators Drs. Javier Martinez-Picado (front right) and Annemarie Wensing (center right), pictured with ICISTEM members including Dr. Gero Hütter, “the Berlin patient’s” physician, and Dr. Maria Salgado. Also pictured are Dr. Rowena Johnston (front, second from right) and Dr. Jeffrey Laurence (back row, right) of amfAR.

Co-Principal Investigators Drs. Javier Martinez-Picado (front right) and Annemarie Wensing (center right), pictured with ICISTEM members including Dr. Gero Hütter, “the Berlin patient’s” physician, and Dr. Maria Salgado. Also pictured are Dr. Rowena Johnston (front, second from right) and Dr. Jeffrey Laurence (back row, right) of amfAR.

What/Who are IciStem, the London patient, and the Düsseldorf patient?

IciStem is a large consortium of HIV researchers and transplant specialists who are currently studying HIV in a cohort of 45 patients who have already received, or will soon receive, stem cell transplants to treat their cancers. Two of these patients – the London patient and the Düsseldorf patient – received cells from donors who had the CCR5-delta32 genetic mutation. Both have stopped taking ART without any signs of HIV returning, but it’s important to note that while the London patient has been off ART for 18 months, the Düsseldorf patient stopped taking ART only four months ago. PLWHIV who stop taking ART typically experience HIV rebound in 2-4 weeks, but the Mississippi child took 28 months to rebound, so although we’re hopeful that the London and Düsseldorf patients are cured, it will take more time to know for sure.

What kinds of things can we learn from these transplant patients?

When Timothy Ray Brown, the Berlin patient, was cured of both his cancer and his HIV following a transplant of CCR5-delta32 cells, the scientific community was unable to determine how crucial the mutation was to his cure outcome. Timothy also received a myeloablative conditioning regimen, as well as total body irradiation, designed to destroy the great majority of his own immune cells, before ultimately receiving two stem cell transplants. IciStem researchers will be able to determine the relative importance of the myeloablation, irradiation, the CCR5-delta32 genetic mutation, and number of transplants by comparing many HIV-positive stem cell transplant recipients in their cohort, because each patient receives a different combination of these factors.

If we learn that the CCR5-delta32 mutation is a critical factor, this finding points a promising way forward for gene therapy. In fact, other researchers have been working on CCR5 gene therapy in HIV for many years, and interesting results are emerging concerning how many of the transplanted cells need to have the genetic mutation in order to make a difference in the clinical outcome. You can learn more here about additional gene therapy strategies currently under investigation by amfAR researchers.

If specific subsets of immune cells are especially effective at clearing small numbers of remaining HIV cells, we can turn that knowledge into a more broadly applicable intervention.We also have the opportunity to learn from the processes by which a stem cell transplant may clear out any remaining vestiges of HIV. If the conditioning regimen before a transplant does not completely clear the HIV-infected cells, we can learn which cells of the newly transplanted immune system finish the job, and how.

If specific subsets of immune cells are especially effective at clearing small numbers of remaining HIV cells, we can turn that knowledge into a more broadly applicable intervention.

By following transplant patients over time, and ultimately confirming they’re cured, we may be able to go back to samples collected earlier during the transplant and recovery process. Researchers could look at cells, proteins, and other substances in their blood to determine whether there are signs that could have predicted a cure, without having to wait years to know for sure. These biomarkers would then be valuable in assessing whether other more broadly applicable interventions have been effective in achieving a cure.

We can also compare the chemotherapy regimens the patients receive for their different cancers, and understand which regimens kill which subsets of cells. We may learn, for example, that some subsets of HIV-infected cells are the most important to target, and that others, even if they contain HIV, might be less important sources of rebounding virus and can be left alone.

And even transplant patients whose HIV we can still detect play an important role in our search for a cure. Because their remaining HIV reservoirs are so small, they may be ideal candidates to test early-generation immunotherapies for their ability to remove any remaining pockets of HIV.

Why do we need transplant patients to learn these things?

There are some things about curing HIV that you can only learn from people who have been cured. In the absence of other interventions so far that cure HIV, we need to learn those lessons from transplant patients.

For example, people living with HIV experience consequences of the persistence of the virus, such as damage to the architecture of their lymph nodes, that can hamper effective immune responses. If we remove the HIV, does their lymph node anatomy and function return to normal? If so, then we have learned that removing HIV may be sufficient for restoring lymph node health, without needing to devise additional interventions.

Similarly, PLWHIV have higher rates of atherosclerosis, a sign of possible heart disease and stroke. If those signs and symptoms return to normal after a stem cell transplant that removed HIV, then perhaps we’ve learned that no further interventions will be needed to deal with heart health after an HIV cure.

Dr. Johnston is an amfAR vice president and director of research.

A New Way to Overcome HIV Latency

Dr. Nicolas Chomont

Dr. Nicolas Chomont

Last month we reviewed the proteasome, a cell structure rarely discussed in the context of HIV but, according to researchers at amfAR’s Institute for HIV Cure Research, one that may offer a novel target in attempts to disrupt viral latency. The proteasome is potentially amenable to attack by two currently used anti-cancer drugs.

This month we highlight the work of amfAR-funded researcher Dr. Nicolas Chomont of the University of Montreal, who is studying another component of normal cells that is also a target of certain cancer therapies and has promise in multi-pronged HIV eradication strategies.

Writing in the journal Nature Communications, Chomont and colleagues examined PD-1, a protein found in higher than expected amounts on the surface of T cells latently infected with HIV. They showed that PD-1 inhibited the ability of certain types of immune stimulation to drive HIV out of its dormant state.

Using T cells from HIV-infected individuals on long-term antiretroviral therapy, the investigators found that blocking PD-1 with pembrolizumab (Keytruda)—a drug currently used in the treatment of many formerly untreatable types of cancer—enabled a second drug, known as a latency reversing agent, to induce HIV escape from latency. Forcing HIV out of latency is a key component of the proposed “shock and kill” approach to curing HIV.

In support of these test-tube studies, Chomont and associates studied an HIV-infected individual who was treated with pembrolizumab in an attempt to cure the person’s malignant melanoma. Markers consistent with latent HIV were decreased by this treatment.

The authors caution that it remains to be determined whether pembrolizumab or other anti-PD-1 cancer drugs, collectively known as immune checkpoint inhibitors, can activate HIV in all the cell types currently thought to contribute to the latent state. But they look forward to pursuing this line of research in the quest for an HIV cure.

Dr. Laurence is amfAR’s senior scientific consultant.


Second patient from Düsseldorf shows similar profile

SEATTLE, WA, March 5, 2019 – Researchers have reported that a stem cell transplant patient from London has not experienced a rebound of his HIV during the past 18 months off antiretroviral therapy (ART). His is the longest duration of ART-free undetectable virus in an adult since the Berlin patient, who is believed to have been cured by a similar procedure. The case was reported at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

The patient is part of amfAR’s ICISTEM research consortium, which has so far enrolled 45 patients with cancer and HIV who have received or soon will receive stem cell transplants.

What does this mean for people living with HIV today?

Another ICISTEM patient was also reported on at CROI—a man from Düsseldorf, Germany, who shows no evidence of viral rebound after a similar transplant procedure, though he has been off treatment only since November. Researchers will follow both patients closely to look for any signs of resurgent HIV.

Lead investigator in the London case, Dr. Ravi Gupta of the University of Cambridge, UK, reported that the HIV-positive man was diagnosed with cancer in 2013 and received a stem cell transplant in 2016. Like the Berlin patient—Timothy Ray Brown—he received donor cells with a genetic mutation (CCR5-delta 32) rendering them resistant to HIV infection. Since discontinuing ART in late 2017, the London patient has shown no trace of the virus.

Comprehensive reservoir analyses were conducted by the ICISTEM consortium, which is co-led by the University Medical Center Utrecht in the Netherlands and the IrsiCaixa AIDS Research Institute in Barcelona, Spain. It includes cure researchers who systematically assess changes in the HIV reservoir resulting from stem cell transplantation, and who provide treatment and monitoring guidance to the collaborating transplant doctors. The researchers are now able to compare changes in the HIV reservoir across the patient cohort.

What does this mean for the future of HIV research?

The ICISTEM group has screened over two million stem cell donors to identify those with the CCR5-delta32 mutation, increasing the chance that new candidate transplant recipients may receive donor cells with this rare genetic mutation. With additional patients in the cohort about to stop ART in what is known as an analytic treatment interruption, researchers are cautiously optimistic that there may soon be additional cases of sustained undetectable virus in the absence of therapy.

“While we fully understand that stem cell transplantation is not a practical way of curing large numbers of people, we can learn a tremendous amount from these cases” said amfAR Chief Executive Officer Kevin Robert Frost. “And we can apply that new knowledge to the development of strategies aimed at a more widely applicable cure.”

Because the London and Düsseldorf patients received an intervention similar in many respects to the case of the Berlin patient, researchers can begin to compare and contrast the procedures. Mr. Brown, for example, underwent two stem cell transplants, whereas the London and Düsseldorf patients received just one. While Brown had intensive chemotherapy and irradiation to prep for the transplant, the London patient had low intensity conditioning and no irradiation, and the Düsseldorf patient received myeloablative conditioning but no irradiation.   

What would it take to call this a cure?

A key question that has vexed researchers is whether or not the CCR5-delta32 mutation was necessary to achieve Mr. Brown’s cure. Since it was present in the cells transplanted into both Mr. Brown and the London and Düsseldorf patients, it will be important to follow them over time.

“Although it’s too early to say for sure, we’re certainly hopeful that the London patient is cured,” said Dr. Rowena Johnston, amfAR vice president and director of research. “amfAR’s  investments in innovative and forward-thinking projects like ICISTEM give us the opportunity to learn which factors will form the scientific basis of a cure for HIV.”